Evelo Biosciences, Inc.
EVLO · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $79 | $84 | $70 | $63 |
| G&A Expenses | $30 | $32 | $22 | $23 |
| SG&A Expenses | $30 | $32 | $22 | $23 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $108 | $115 | $92 | $86 |
| Operating Income | -$108 | -$115 | -$92 | -$86 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$5 | -$6 | -$1 | $1 |
| Pre-Tax Income | -$114 | -$122 | -$93 | -$85 |
| Tax Expense | $1 | $0 | $0 | $0 |
| Net Income | -$115 | -$122 | -$94 | -$86 |
| % Margin | – | – | – | – |
| EPS | -26.28 | -46.18 | -47.45 | -53.49 |
| % Growth | 43.1% | 2.7% | 11.3% | – |
| EPS Diluted | -26.28 | -46.18 | -47.45 | -53.49 |
| Weighted Avg Shares Out | 4 | 3 | 2 | 2 |
| Weighted Avg Shares Out Dil | 4 | 3 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $5 | $4 | $2 | $1 |
| Depreciation & Amortization | $2 | $2 | $2 | $0 |
| EBITDA | -$106 | -$115 | -$90 | -$84 |
| % Margin | – | – | – | – |